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To the Editor:
Recently in the Journal of 
Thoracic Oncology, Bollig-Fischer 
et al.1 nicely characterized racial diver-
sity in the frequency of so-called action-
able mutations in non–small-cell lung 
cancer. Advanced sequence testing with 
the hope of identifying such abnormali-
ties has become part of a standard evalu-
ation of most metastatic non–small-cell 
lung cancers. By evaluating a large 
series, their report underscores ethical 
issues that will occasionally occur with 
incidentally discovered findings from 
these assays.
For example, the authors mention 
the discovery of a “rare single nucleo-
tide germ line variant.” Whereas in this 
case, the significance of the variant may 
be unknown, what should be done if a 
molecular abnormality is discovered, 
which definitely implies a hereditary 
cancer syndrome? Should obtaining 
informed consent from the patient before 
advanced sequencing include a discus-
sion of such possible findings?
Theirs was a retrospective study 
wherein the data were compiled accord-
ing to the “Helsinki Declaration and 
approved by the Wayne State University 
School of Medicine.” If an abnormality 
had been identified in a patient’s tumor, 
which is typically associated with an 
inherited cancer syndrome, should they 
contact that patient?
With next generation and other 
advanced sequencing techniques, 
uncertainties regarding the significance 
of certain molecular abnormalities 
found during sequencing (e.g., mod-
erate-penetrance susceptibility genes 
and variants of unknown significance) 
might occur. Also, even if subsequent 
germ line testing identifies a very spe-
cific germ line molecular abnormality 
associated with an inherited syndrome, 
penetrance of the phenotype might be 
largely unknown compared with the 
same result seen based on germ line 
testing done for a patient with a per-
sonal and family history suggesting the 
inherited syndrome (not incidentally 
discovered).
How do we advise patients 
of these possible outcomes of a test 
ordered to identify actionable molecu-
lar abnormalities when that test has the 
potential to identify changes suggesting 
an inherited syndrome?
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To the Editor:
Dr. Sorscher’s letter or comments 
could be used as a conversation starter 
for many academic laboratories and 
Institutional Review Boards overseeing 
human subject research, about the pos-
sibility of identifying actionable molec-
ular abnormalities in genomic research 
using patient specimens. Upon reading 
his letter the first thoughts that came to 
my mind surround what it means for a 
cancer gene aberration to be actionable, 
considering clinical diagnostic labora-
tory practices and the guidelines set 
by regulatory agencies for genetic or 
molecular testing.
Under the framework of clinical 
genomic testing the objective of the 
test, be it a hereditary cancer panel (test-
ing for variants in DNA from blood or 
saliva) or somatic mutation panel (test-
ing DNA from tumor tissue), specifi-
cally categorizes the test and nature of 
the significance of potential test results. 
It can be seen that major testing provid-
ers generally operate in the space of one 
or the other, not both. Regulatory agen-
cies such as the College of American 
Pathologists rightly dictate that testing 
panels comprise only gene features, 
inherited allelic variants or somatic 
lesions that if identified have clinical 
utility, i.e., unequivocal evidence to 
be beneficial to understanding patient 
risk or prognosis, or to inform deci-
sion-making with regard to treatment. 
Of course the number of clinically 
useful or actionable targets is poten-
tially an ever evolving list and major 
stakeholders in the discussion include 
test developers and providers, clini-
cal/translational researchers, payers, 
consumers, and regulators. The use of 
high-throughput methods, such as next-
generation sequencing or cytogenomic 
approaches, in clinical laboratory mul-
tigene testing hold potential to capture 
a lot of data. But, irrespective of total 
base pairs sequenced or expanse of 
genomic elements in the preprocessed 
data, regulatory agencies hold that the 
specific mutations or variants being 
tested for and reported remain strictly 
defined. To this end bioinformatic 
methods and data quality control are 
spelled out in detail in clinical labora-
tory standard operating procedures and 
routinely reviewed.
In conducting genomic research 
on human specimens, it now strikes me 
that it would probably be useful for pre-
clinical researchers to be aware of the 
current state of clinical testing: know 
what specific cancer variant testing is 
being provided by industry-leading 
clinical laboratories and know the stan-
dards set by regulatory agencies; and 
thus be in tune with what it means for 
a cancer genetic aberration to be clini-
cally actionable. This will prepare an 
